References:
1. IMS Health, National Disease and Therapeutic Index, Custom Report, 5/17/07.
2. Del Rosso JQ, Webster, GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791-802. 3. Data on file, CollaGenex Pharmaceuticals, Inc. 4. Millikan L. The proposed inflammatory pathophysiology of rosacea: Implications for treatment. SKINmed. 2003;2(1):43-47. 5. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: A randomised, double-blind, placebo-controlled study. Lancet. 2007;369(9560):482-490.